LOW-RISK OF VIRAL-INFECTION AFTER ADMINISTRATION OF VAPOR-HEATED FACTOR-VIII CONCENTRATE

被引:50
作者
MANNUCCI, PM
SCHIMPF, K
ABE, T
ALEDORT, LM
ANDERLE, K
BRETTLER, DB
HILGARTNER, MW
KERNOFF, PBA
KUNSCHAK, M
MCMILLAN, CW
PRESTON, FE
RIVARD, GE
机构
[1] ANGELO BIANCHI BONOMI HEMOPHILIA & THROMBOSIS CTR,MILAN,ITALY
[2] REHABIL FDN,REHABIL HOSP & HEMOPHILIA CTR HEIDELBERG,HEIDELBERG,GERMANY
[3] TEIKYO UNIV,SCH MED,DEPT MED,TOKYO 173,JAPAN
[4] CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029
[5] IMMUNO AG WIEN,VIENNA,AUSTRIA
[6] MED CTR CENT MASSACHUSETTS,NEW ENGLAND COMPREHENS HEMOPHILIA CTR,WORCESTER,MA
[7] CORNELL UNIV,SCH MED,DEPT PEDIAT,ITHACA,NY 14853
[8] ROYAL FREE HOSP,CTR HEMOPHILIA,LONDON,ENGLAND
[9] ROYAL FREE HOSP,HEMOSTASIS UNIT,LONDON,ENGLAND
[10] UNIV N CAROLINA,SCH MED,DEPT PEDIAT,CHAPEL HILL,NC 27514
[11] ROYAL HALLAMSHIRE HOSP,DEPT HEMATOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
[12] HOSP ST JUSTINE,MONTREAL,QUEBEC,CANADA
关键词
D O I
10.1046/j.1537-2995.1992.32292180141.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A multicenter prospective study was carried out to evaluate whether a vapor-heated factor VIII concentrate transmitted blood-borne viral infections over a surveillance period of 15 months. Thirty-five patients with hemophilia and von Willebrand disease who had never received any blood components were treated. Twenty-eight were analyzed and found not to have non-A,non-B hepatitis. Sera from 20 of these 28 patients were also tested for the antibody to the hepatitis C virus. None had seroconverted during the follow-up period. None of the patients analyzed developed markers of the hepatitis B virus (n = 17) or the human immunodeficiency virus (n = 31). This vapor-heated factor VIII concentrate carries a low risk of transmitting hepatitis and human immunodeficiency virus infection.
引用
收藏
页码:134 / 138
页数:5
相关论文
共 20 条
[1]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[2]  
BRACKMANN HH, 1988, LANCET, V2, P967
[3]  
BRETTLER DB, 1989, BLOOD, V73, P2067
[4]   ISSUES ASSOCIATED WITH SAFETY TESTING OF BLOOD PRODUCTS IN ENDEMIC AREAS [J].
EIBL, J ;
EDER, G ;
ANDERLE, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (04) :575-576
[5]   NON-A NON-B HEPATITIS AFTER TRANSFUSION OF FACTOR-VIII IN INFREQUENTLY TREATED PATIENTS [J].
FLETCHER, ML ;
TROWELL, JM ;
CRASKE, J ;
PAVIER, K ;
RIZZA, CR .
BRITISH MEDICAL JOURNAL, 1983, 287 (6407) :1754-1757
[6]   IF NOTHING GOES WRONG, IS EVERYTHING ALL RIGHT - INTERPRETING ZERO NUMERATORS [J].
HANLEY, JA ;
LIPPMANHAND, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 249 (13) :1743-1745
[7]  
HASEGAWA DK, 1987, LANCET, V1, P449
[8]   HIGH-RISK OF NON-A NON-B HEPATITIS AFTER A 1ST EXPOSURE TO VOLUNTEER OR COMMERCIAL CLOTTING FACTOR CONCENTRATES - EFFECTS OF PROPHYLACTIC IMMUNE SERUM GLOBULIN [J].
KERNOFF, PBA ;
LEE, CA ;
KARAYIANNIS, P ;
THOMAS, HC .
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 60 (03) :469-479
[9]   FACTOR-VIII-C INHIBITOR ASSOCIATED WITH MONOCLONAL-ANTIBODY PURIFIED FVIII CONCENTRATE [J].
KESSLER, CM ;
SACHSE, K .
LANCET, 1990, 335 (8702) :1403-1403
[10]   PHARMACOKINETICS OF A NEW HEAT-TREATED CONCENTRATE OF FACTOR-VIII ESTIMATED BY MODEL-INDEPENDENT METHODS [J].
LONGO, G ;
MATUCCI, M ;
MESSORI, A ;
MORFINI, M ;
ROSSIFERRINI, P .
THROMBOSIS RESEARCH, 1986, 42 (04) :471-476